NCT06607939View on ClinicalTrials.gov

ORB-021 In Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 21, 2024

Primary Completion Date

December 29, 2026

Study Completion Date

February 28, 2027

Conditions
Advanced Solid Tumors Cancer
Interventions
DRUG

ORB-021

ORB-021 is dosed via IV infusion

Trial Locations (2)

77030

RECRUITING

MDAC, Houston

85258

RECRUITING

Honor Health Clinical Research, Scottsdale

Sponsors
All Listed Sponsors
lead

Orionis Biosciences Inc

INDUSTRY

NCT06607939 - ORB-021 In Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter